OS 01-08 IMPACT OF HYPERTENSION TREATMENT ON IMMUNOSENESCENCE PARAMETERS.

OBJECTIVE: Inflammation by adaptive immune response of T cells was associated with hypertension (HTN) in previous animal study. And recent human research demonstrated that patients with HTN had a higher level of serum immunosenescence (IS) parameters, which were CD28null fraction of CD8 + (CD28nullCD8) and CD57 + fraction of CD8 + (CD57 + CD8) T cell. However there were limited data regarding impact of HTN treatment on these IS parameters.

DESIGN AND METHOD: Multicenter longitudinal observational study from April 2013 to August 2015. A total of 87 consecutive hypertensive patients (SBP > 140 mmHg or DBP > 90 mmHg) were enrolled and followed up for 6 months. The clinical characteristics and routine laboratory values were examined at baseline visit. Blood pressure (BP), heart rate (HR), fraction of CD28nullCD8 + and CD57 + CD8 + T cell were measured at baseline and 6 months follow-up visits. Multivariable regression analysis was performed to assess the factors influencing the change of these IS parameters.

RESULTS: HTN was controlled in 56 patients (64.4%). After HTN treatment, systolic BP and diastolic BP were decreased from 147.7 ± 11.1mmHg to 135.9 ± 12.6mmHg (p-value = 0.001) and from 87.2 ± 10.2mmHg to 81.6 ± 9.6mmHg (p-value = 0.001). CD28nullCD8 T cell was significantly decreased from 41.1 ± 17.9% to 37.5 ± 18.8% (p-value = 0.01) but CD57 + CD8 T cell was not correlated with HTN treatment. (42.2 ± 17.5% vs 42.7 ± 18.4%, p-value = 0.596). In multivariate analysis, only age was associated with change in CD28nullCD8 + T cell. Younger patients demonstrated greater reduction in CD28nullCD8 T cell. (p-value = 0.019) CONCLUSIONS:: IS parameter, CD28nullCD8 T cell was significantly decreased with HTN treatment, especially in younger patients.